Reproductive · PANCE / PANRE

Pelvic Organ Prolapse

Descent of pelvic organs through pelvic floor defects: cystocele, rectocele, enterocele, uterine.

Also known as: POP, cystocele, rectocele, uterine prolapse, vaginal prolapse, enterocele

Overview

Symptomatic descent of one or more of the anterior vaginal wall (cystocele), posterior vaginal wall (rectocele), uterus/apex, or vaginal vault (post-hysterectomy) through the pelvic floor. Severity is graded by the POP-Q (Pelvic Organ Prolapse Quantification) system.

Epidemiology

Lifetime risk of surgery for prolapse or incontinence ~13%. Prevalence increases with age and parity; nearly 50% of parous women have some degree of prolapse on examination but only a minority are symptomatic.

Try two board-style Pelvic Organ Prolapse questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1ReproductiveMedium
A 64-year-old G4P4 postmenopausal woman presents with a 6-month history of vaginal pressure and a sensation that 'something is falling out' that worsens with prolonged standing and improves when she lies down. She also reports needing to splint the posterior vaginal wall to complete bowel movements. She had four vaginal deliveries, the largest infant weighing 4,200 g. On pelvic examination with Valsalva, the cervix descends to 3 cm beyond the hymen without complete vaginal eversion. Which of the following is the most likely diagnosis?
  • AStage I uterine prolapse
  • BStage III uterine prolapse
  • CCystocele
  • DStage II uterine prolapse
Reveal answer & full explanation
Correct answer: B — Stage III uterine prolapse
  • AStage I uterine prolapse
  • BStage III uterine prolapse
  • CCystocele
  • DStage II uterine prolapse

Why Stage III uterine prolapse is correct

  • Pelvic organ prolapse is staged by the POP-Q system using the most distal point of the leading edge relative to the hymen.
  • Stage 0 = no descent; stage I = leading edge more than 1 cm above the hymen; stage II = leading edge within 1 cm of the hymen; stage III = leading edge more than 1 cm beyond the hymen without complete eversion; stage IV = complete eversion.
  • This patient's cervix descends to 3 cm beyond the hymen with bulge symptoms and obstructed defecation, placing the leading edge well beyond +1 cm and consistent with stage III.

Why the others are wrong

  • Stage I uterine prolapse — describes a leading edge more than 1 cm above the hymen and would not produce a visible bulge or symptoms; choosing it under-stages the obvious protrusion beyond the hymen.
  • Stage II uterine prolapse — describes a leading edge within 1 cm above or below the hymen; a cervix reaching 3 cm past the hymen lies well outside that window, so this under-stages the measured descent.
  • Cystocele — anterior vaginal wall prolapse from bladder descent; her posterior splinting may reflect a coexisting defect, but the leading point is the cervix, so anchoring on a compartment defect misses the primary uterine prolapse.
Question 2ReproductiveMedium
A 70-year-old G5P5 woman has stage II uterine prolapse with vaginal pressure on prolonged standing. She is sexually active, has well-controlled hypertension, type 2 diabetes, and prior CABG, and wishes to avoid surgery. Exam: cervix descends to the hymen with Valsalva and mild anterior wall descent. Which of the following is the most appropriate first-line management?
  • AVaginal pessary placement
  • BSystemic estrogen therapy
  • CTopical vaginal estrogen
  • DVaginal dilator therapy
Reveal answer & full explanation
Correct answer: A — Vaginal pessary placement
  • AVaginal pessary placement
  • BSystemic estrogen therapy
  • CTopical vaginal estrogen
  • DVaginal dilator therapy

Why Vaginal pessary placement is correct

  • First-line management of symptomatic pelvic organ prolapse in patients who wish to avoid surgery or have significant surgical risk is a vaginal pessary combined with pelvic floor muscle training
  • Pessaries are effective in 60-80% of patients, are reversible, and preserve sexual function with appropriate device selection (e.g., ring with or without support)

Why the others are wrong

  • Systemic estrogen therapy — systemic estrogen does not restore pelvic support and adds thromboembolic and cardiovascular risk in a woman with prior coronary bypass surgery
  • Topical vaginal estrogen — can improve tissue quality and is often used as adjunct therapy with a pessary but does not correct prolapse
  • Vaginal dilator therapy — dilators are used for vaginal stenosis and dyspareunia; they stretch the vaginal canal and provide no support for the descending cervix or anterior wall
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Pelvic Organ Prolapse outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Vaginal childbirth (particularly multiple, instrumental, or with large infants)
  • Aging, menopause and estrogen deficiency
  • Obesity, chronic constipation or chronic cough (COPD)
  • Connective tissue disorders (Ehlers-Danlos, Marfan)
  • Prior pelvic surgery (especially hysterectomy)
  • Heavy lifting, family history

Pathophysiology

Pelvic floor support depends on the levator ani musculature, endopelvic fascia, and uterosacral/cardinal ligament complex. Childbirth and aging weaken and stretch these structures, allowing descent of pelvic organs. Estrogen loss reduces collagen content of vaginal tissues.

Clinical presentation

Symptoms

  • Vaginal bulge or 'something falling out' — most specific symptom
  • Pelvic pressure or heaviness worsening with prolonged standing
  • Urinary symptoms: incomplete emptying, urgency, splinting (manual reduction to void), recurrent UTI
  • Bowel symptoms: incomplete defecation, need to splint the posterior vaginal wall or perineum to defecate, constipation
  • Sexual symptoms: dyspareunia, decreased sensation, embarrassment

Signs / physical exam

  • POP-Q assessment with patient in lithotomy and on Valsalva — describes leading edge of anterior, posterior, and apical compartments relative to the hymen
  • Stage 0 (no prolapse) to Stage IV (complete eversion)
  • Speculum or Sims retractor used to isolate compartments
  • Look for ulceration of exposed tissue in advanced prolapse

Differential diagnosis

  • Stress urinary incontinence — Leakage with cough/sneeze/Valsalva; may coexist with cystocele or be unmasked after prolapse repair
  • Urinary tract infection — Dysuria, frequency, urgency; UA positive
  • Vaginal mass (cyst, malignancy) — Discrete mass not reducible; biopsy if suspicious
  • Urethral diverticulum — Anterior vaginal wall tender mass, post-void dribbling, dyspareunia; MRI diagnostic
  • Hemorrhoids or rectal prolapse — Anorectal symptoms; rectal exam distinguishes

Diagnostic workup

Diagnostic criteria

Clinical exam using the POP-Q system. Symptoms are required for treatment; asymptomatic prolapse generally needs no intervention.

Labs

  • Urinalysis to exclude UTI
  • Post-void residual to assess voiding dysfunction

Imaging

  • Imaging not routinely required; consider urodynamics if concomitant incontinence and planning surgery
  • MRI or dynamic ultrasound only in complex or recurrent cases

Diagnostic algorithm

POP-Q StageLeading Edge Relative to Hymen
0No prolapse
I>1 cm above hymen
IIWithin 1 cm of hymen (above or below)
III>1 cm below hymen but not full eversion
IVComplete eversion of vagina
POP-Q staging system for pelvic organ prolapse.

Treatment

First-line

  • Observation if mild and minimally symptomatic
  • Lifestyle: weight loss, treat constipation (fiber, hydration, stool softeners), manage chronic cough, avoid heavy lifting
  • Pelvic floor muscle training (Kegel exercises) +/- supervised physical therapy — may reduce symptoms in mild prolapse
  • Vaginal pessary — first-line nonsurgical management; fitted by trained clinician; many shapes (ring, Gellhorn, donut, cube); requires periodic cleaning and follow-up
  • Vaginal estrogen (estradiol cream or tablet, conjugated equine estrogen cream) in postmenopausal women to improve tissue quality and pessary tolerance

Surgical (when symptoms warrant and conservative measures fail)

  • Reconstructive: anterior or posterior colporrhaphy, apical suspension (uterosacral or sacrospinous ligament suspension; sacrocolpopexy — abdominal/laparoscopic, gold standard for apical prolapse)
  • Vaginal hysterectomy with apical suspension is common when uterine prolapse present
  • Obliterative (colpocleisis): for women who do not desire vaginal function; lower morbidity, very high success
  • Transvaginal synthetic mesh for prolapse repair was banned by FDA in 2019 due to high complication rates

Second-line / adjunct

  • Anti-incontinence procedure (midurethral sling) may be performed concurrently in selected patients with stress incontinence (occult or overt)

Complications

  • Vaginal ulceration and bleeding from advanced prolapse or ill-fitting pessary
  • Recurrent UTIs from incomplete emptying
  • Defecatory dysfunction and chronic constipation
  • Recurrence after surgical repair (~10-30% over 5 years)
  • Surgical complications: mesh erosion (with sacrocolpopexy), de novo dyspareunia, urinary or fecal incontinence

PANCE pearls

  • Pessaries are first-line for symptomatic prolapse — they are safe, effective in 60-80%, and avoid surgery; offer to all patients including those who desire future fertility.
  • Vaginal estrogen markedly improves tissue quality in postmenopausal women and is appropriate adjunct to either pessary or surgical management.
  • Stage of prolapse does not strictly determine the need for treatment — symptom burden and patient preference do.
  • Always inquire about hidden ('occult') stress incontinence after reducing prolapse, as some women develop new SUI postoperatively.
  • Transvaginal mesh for prolapse repair is no longer FDA-approved; mesh remains used in abdominal sacrocolpopexy and for midurethral slings, which have a different regulatory status.

References

  • ACOG PB 214 — ACOG Practice Bulletin 214: Pelvic Organ Prolapse (Obstet Gynecol 2019, reaffirmed)
  • AUGS — AUGS Position Statement on Vaginal Mesh (2019)
  • OPTIMAL Trial — Barber et al., JAMA 2014 — uterosacral vs sacrospinous suspension

Practice Reproductive questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.